Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
25.21
+0.19 (0.78%)
At close: Oct 2, 2026, 4:00 PM EDT
25.21
+0.01 (0.02%)
After-hours: Oct 2, 2026, 7:30 PM EDT

Pacira BioSciences Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Pacira BioSciences stock has a consensus rating of "Buy" and an average price target of $30. The average 1-year stock price forecast is 19.02% higher than the current stock price, while the lowest is $23 (-8.75%) and the highest is $38 (+50.76%).

Price Target: $30 (+19.02%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$23$30$30$38
Change-8.75%+19.02%+19.02%+50.76%

Analyst Ratings

The average analyst rating for Pacira BioSciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingApr '26May '26Jun '26Jul '26Aug '26Sep '26
Strong Buy332234
Buy111111
Hold222223
Sell111111
Strong Sell000000
Total776679

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Oppenheimer
Oppenheimer
Buy
Initiates
$32
BuyInitiates$32+26.96%Sep 23, 2026
Truist Financial
Truist Financial
Buy
Reiterates
n/a
BuyReiteratesn/an/aSep 21, 2026
Leerink Partners
Leerink Partners
Hold
Initiates
$28
HoldInitiates$28+11.09%Sep 9, 2026
Barclays
Barclays
Hold
Maintains
$25
HoldMaintains$25-0.81%Aug 17, 2026
J.P. Morgan
J.P. Morgan
Sell
Maintains
$23
SellMaintains$23-8.75%Aug 10, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
754.36M
from 726.41M
Increased by 3.85%
Revenue Next Year
789.70M
from 754.36M
Increased by 4.69%
EPS This Year
2.89
from 2.65
Increased by 9.07%
EPS Next Year
3.44
from 2.89
Increased by 19.09%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
541.53M666.82M674.98M700.97M726.41M754.36M
Revenue Growth
26.04%23.14%1.22%3.85%3.63%3.85%
Gross Profit
401.28M467.53M490.31M530.54M576.66M592.55M
Gross Margin
74.10%70.11%72.64%75.69%79.39%78.55%
Operating Income
89.92M70.93M87.32M97.57M33.30M155.53M
Net Income
41.98M15.91M41.96M-99.56M7.03M41.95M
EPS
----2.652.89
EPS Growth
-----17.19%9.07%
Forward PE
15.4311.6410.237.107.538.72
Free Cash Flow
----136.66M183.37M
No. Analysts
-----8
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High759.4M
Avg754.4M
Low747.8M

Revenue Growth

Revenue Growth202620272028
High
4.5%
Avg
3.8%
Low
2.9%

EPS Forecast

EPS202620272028
High2.99
Avg2.89
Low2.72

EPS Growth

EPS Growth202620272028
High
12.8%
Avg
9.1%
Low
2.5%